ABBV vs JNJ: AbbVie Is Executing Its Pipeline Pivot Better Than Expected — JNJ Remains the More Reliable Dividend
AbbVie spent years with nearly 60% of its revenue from a single drug — Humira. When biosimilars arrived in 2023, everyone expected a collapse. Instead, Skyrizi and Rinvoq absorbed the blow faster than almost anyone predicted. Now ABBV is growing again. JNJ, meanwhile, is the quieter compounder — diversified between pharma and MedTech, 60+ years of dividend increases, and fortress-level financials.
The Core Difference
AbbVie was spun out of Abbott Laboratories in 2013 as a pharma pure-play. Its entire early existence depended on Humira — the world's best-selling drug for over a decade, treating rheumatoid arthritis, Crohn's, psoriasis, and other immune conditions. When biosimilars arrived in the US in 2023, the threat was existential. The transition that has happened since — building Skyrizi and Rinvoq into multi-billion revenue products — is one of the more impressive pipeline executions in recent pharmaceutical history.
JNJ is built different. The MedTech division (Medtronic competitor-level devices, surgical robotics via DePuy Synthes and Abiomed acquisitions) means that roughly 40% of JNJ's revenue comes from medical devices — a completely different business model from drug patents and biosimilar cliffs. The diversity is JNJ's main advantage over any pure pharma peer.
Business Comparison
- Pharma-only: immunology, oncology, neuroscience
- Skyrizi + Rinvoq replacing Humira faster than expected
- ~4–5% dividend yield
- ImmunoGen acquisition (oncology ADCs)
- Botox therapeutic pipeline growing
- Concentration risk — fewer products than JNJ
- Pharma + MedTech (two major divisions)
- Dividend King: 60+ years of increases
- ~3% yield, AA credit rating
- Oncology + immunology + MedTech portfolio
- Talc litigation overhang (Kenvue spinoff did not eliminate)
- Lower growth, more stability
The Income Comparison
ABBV yields more — roughly 4–5% vs JNJ's ~3%. But the quality of the income differs. JNJ's dividend is AAA-credit backed with 60+ years of growth and a payout from two diversified business units. ABBV's dividend, while growing, is still dependent on whether Skyrizi and Rinvoq continue their strong commercial uptake and whether new pipeline assets (oncology, neuroscience) can maintain momentum beyond 2027.
The ABBV bull case for income investors is that Skyrizi and Rinvoq peak sales guidance (~$27B combined by 2027) actually understates potential. If AbbVie can successfully expand indications and acquire into oncology (ImmunoGen being the key bet), the dividend growth rate could outpace JNJ's more modest single-digit increases.
Who Should Buy Which
Technical Signals — What to Watch
Both ABBV and JNJ trade as defensive income stocks — they tend to outperform in market downturns and underperform in aggressive risk-on rallies. Key catalysts are earnings (particularly quarterly Skyrizi/Rinvoq sales numbers for ABBV) and FDA pipeline milestones.
- RSI: Both stocks rarely reach extreme RSI levels — RSI below 40 on either name often represents a buying opportunity in the absence of fundamental deterioration.
- MACD: Watch for ABBV MACD crossovers around earnings — Skyrizi/Rinvoq beat-or-miss dynamics drive multi-week trend changes.
- Volume: Unusual accumulation volume on JNJ often precedes MedTech division guidance updates or acquisition announcements.
APEX scores both stocks daily across RSI, MACD, moving averages, volume, and 52-week position. Updated every market day.
Compare ABBV vs JNJ Live →